Global Shingles Vaccine Market Size To Exceed USD 25.6 Billion By 2035 | CAGR of 15.8%
Category: HealthcareGlobal Shingles Vaccine Market to Exceed USD 25.6 Billion by 2035
According to a research report published by Spherical Insights & Consulting, the Global Shingles Vaccine Market Size is Expected to Grow from USD 5.1 Billion in 2024 to USD 25.6 Billion by 2035, at a CAGR of 15.8% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 225 pages with 119 Market data tables and figures & charts from the report on the "Global Shingles Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Product (Shingrix, Zostavax, and Skyzoster), By Vaccine Type (Recombinant Vaccine and Live Attenuated Vaccine), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/shingles-vaccine-market
The shingles vaccine market includes products and services intended to vaccinate against herpes zoster. It covers the creation, distribution, and administration of vaccines in a range of medical environments. Improvements in recombinant and mRNA-based vaccine technologies, which provide increased safety, efficacy, and durability, are driving the growth of the shingles vaccine industry. Demand for vaccines, especially among seniors, is driven by ageing populations, the incidence of immunocompromising diseases, and a growing emphasis on preventative healthcare. Public awareness efforts and government-led immunisation programs also aid in uptake. Particularly in developing nations, vaccination formulation innovations like lyophilised mRNA and adjuvant optimisation improve accessibility and administration while boosting immune response and stability. Although mergers and acquisitions are still minimal because of the segment's niche character, strategic alliances and licensing agreements are speeding up research and development as well as the availability of vaccines. However, there are a number of obstacles to overcome, including the high cost of vaccines, the lack of adequate healthcare infrastructure, vaccination reluctance brought by false information, and the need for cold chain storage in isolated areas. Aside from these obstacles, it is anticipated that ongoing innovation and public-private initiatives will increase coverage and sustain the shingles vaccine market's steady international expansion.
The shingrix segment dominated the market in 2024 and is expected to expand at a significant CAGR during the forecast period.
Based on the product, the shingles vaccine market is divided into shingrix, zostavax, and skyzoster. Among these, the shingrix segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Shingrix dominates due to its recombinant, adjuvanted vaccine formulation, which offers superior efficacy and longer-lasting protection compared to conventional live attenuated vaccinations. Since Shingrix was approved by health authorities and included in adult vaccination programs, its use and acceptability have risen. Since the vaccine is successful in preventing shingles and postherpetic neuralgia, it is the suggested choice for both patients and medical professionals.
The recombinant vaccine segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the vaccine type, the shingles vaccine market is divided into recombinant vaccine and live attenuated vaccine. Among these, the recombinant vaccine segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Compared to traditional live attenuated vaccinations, recombinant vaccines, such as Shingrix and SkyZoster, offer improved efficacy and safety, making them perfect for older and immunocompromised people. Their market domination is strengthened by inclusion in national immunisation programs and support from international health agencies. The leadership in this category will be further maintained by ongoing research into adjuvant and formulation enhancements.
North America is expected to hold the majority share of the global shingles vaccine market during the forecast period.
Get more details on this report -
North America is likely to dominate the shingles vaccine market due to its strong healthcare infrastructure, high public awareness, and extensive use of innovative vaccine technologies. Government-led vaccination programs for older seniors and immunocompromised people produce steady demand. The region benefits from rapid regulatory approvals and continued investment in vaccine development. In the United States, CDC-backed adult immunisation campaigns and increasing vaccine availability have raised uptake. Furthermore, key vaccine producers in North America continue to extend their portfolios and distribution networks, consolidating the region's dominance and ensuring consistent market growth over the forecast period.
Asia Pacific is anticipated to grow at the fastest pace in the global shingles vaccine market during the forecast period. The Asia-Pacific shingles vaccine market is rapidly developing, owing to a large at-risk population, increased disposable incomes, and improved healthcare access. Government initiatives, strengthened vaccination policy, and increased public awareness, particularly in low and middle-income countries, are propelling vaccine acceptance. In China, biotech advancements, NMPA approvals, and strong government support increase market appeal. In Japan, the ageing population, pro-vaccination efforts, and PMDA-led immunisation campaigns all contribute to increased demand. The region's significance in worldwide vaccine adoption is projected to rise as new recombinant vaccines are approved.
Major vendors in the global shingles vaccine market are Merck & Co., Inc., SK bioscience, Curevo In, GeneOne Life Science, GlaxoSmithKline plc., Pfizer Inc., CanSinoBIO, Vaccitech, Green Cross Corp, and Others
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
In June 2024, Dynavax Technologies Corporation reported the enrolment and dosing of the first person in a Phase 1/2 clinical trial to examine Z-1018's safety, tolerability, and immunological response. This potential vaccine candidate is being investigated to prevent shingles (herpes zoster), a painful illness caused by the varicella-zoster virus.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the shingles vaccine market based on the below-mentioned segments:
Global Shingles Vaccine Market, By Product
- Shingrix
- Zostavax
- Skyzoster
Global Shingles Vaccine Market, By Vaccine Type
- Recombinant Vaccine
- Live Attenuated Vaccine
Global Shingles Vaccine Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?